Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

When do you pursue additional workup for incidental thrombocytosis in hospitalized patients?

1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Medical University of South Carolina

Since most acutely ill patients will have lab evidence of acute illness, including thrombocytosis, I usually do not work it up during the hospital stay. But it should be stated in the discharge summary and followed up post-discharge.

How is the CARES kappa subgroup data changing your approach to newly diagnosed kappa AL amyloidosis?

4 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

The CARES trial was a negative phase 3 trial comparing standard-of-care therapy with or without anselamimab (an anti-amyloid monoclonal antibody) for newly diagnosed amyloidosis.While the overall results were negative, there was a subgroup analysis that was prespecified that showed a significant sur...

How would you work up a patient with cutaneous mastocytosis?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Vanderbilt University Medical Center

Is a BM biopsy a must when there is skin involvement? I think a bone marrow biopsy for cutaneous mastocytosis is most helpful when it is in the setting of a patient being referred by dermatology for a skin biopsy result showing TMEP (telangiectasia macularis eruptive perstans) since TMEP has been ...

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

5
2 Answers

Mednet Member
Mednet Member
Infectious Disease · Harbor - UCLA Medical Center

PCV-21 was recently approved by the FDA and supported by ACIP. At this early stage (August 2024), CDC has not finalized guidance on PCV-21, so we do not know how the vaccine schedule will be changed. An important distinction is that PCV-21 covers different serotypes of pneumococcus, as outlined in t...

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?

3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Case Western Reserve University School of Medicine

COVID-19 disease in children seems to be less severe than adults based on the current literature and our personal experience at Children's Hospitals. Among adults, the coagulopathy is beginning to be described with elevated inflammatory markers and other markers of coagulation activation, including ...

When, if ever, would you select a three-drug regimen instead of four-drug regimen in patients with newly diagnosed Multiple Myeloma?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Utah Health

Thank you for this question. For older, transplant-ineligible patients, there is no data that patients live longer or better (the true goals of treatment) with four drugs instead of three drugs. Yes, the responses are better, and we hope this may translate to longevity over time, but we do not know ...

How do you decide between anticoagulation or portal vein recanalization in a patient with portal vein thrombosis?

1
1 Answers

Mednet Member
Mednet Member
Hepatology · Northwestern

It depends on cirrhotic vs non-cirrhotic. For cirrhotic, best to reference the AASLD 2020 guidance here - Northup et al., PMID 33219529.For non-cirrhotic: important to determine the etiology as well as evaluate for a hypercoagulable state, including checking for JAK2 and CALR.If acute and non-occlus...

Is there a role for anti-fibrinolytic agents in patients with hyperfibrinolytic disseminated intravascular coagulation?

1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

DIC is a complex clinicopathologic syndrome. There are no randomized trials to support evidence-based practice. The following principles apply: 1) antifibrinolytics should not be used in patients with organ failure or those that are asymptomatic. One could justify their use in this group of patients...

How do you approach the risk/benefit discussion for IV iron in a patient with concomitant severe iron deficiency and elevated hematocrit due to supra-physiologic testosterone supplementation?

1 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

I only administer iron if symptomatic (pagophagia, RLS, etc). I have not seen iron deficiency with testosterone prior to phlebotomy. When it is required, I literally walk both sides of the aisle. If a non-phlebotomized patient presented with ID, I would work it up like any other. If I have to treat,...